Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

This billing/coding article states that the Biocept Target Selector HER2 Assay and the AR‑V7 Protein Test are considered reasonable and necessary under LCD L38643 and should be reported using CPT 81479 with 1 unit of service. Claims must include the appropriate DEX Z‑Code adjacent to the CPT line (specific fields differ for Part A vs Part B and electronic vs paper claims) and an appropriate ICD‑10‑CM diagnosis code; clinical eligibility details are defined in the referenced LCD.

"Biocept Target Selector HER2 Assay is identified as reasonable and necessary for coverage per the related LCD L38643."

Sign up to see full coverage criteria, indications, and limitations.